DE69827387D1 - Verwendung von pramipexol zur behandlung von restless-legs-syndrom - Google Patents

Verwendung von pramipexol zur behandlung von restless-legs-syndrom

Info

Publication number
DE69827387D1
DE69827387D1 DE69827387T DE69827387T DE69827387D1 DE 69827387 D1 DE69827387 D1 DE 69827387D1 DE 69827387 T DE69827387 T DE 69827387T DE 69827387 T DE69827387 T DE 69827387T DE 69827387 D1 DE69827387 D1 DE 69827387D1
Authority
DE
Germany
Prior art keywords
pramipexol
restless legs
legs syndrome
treating restless
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69827387T
Other languages
English (en)
Other versions
DE69827387T2 (de
Inventor
H Oertel
Dieter Meier
Baltazar Gomez-Mancilla
J Montplaisir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Pharmacia and Upjohn Co, Upjohn Co filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE69827387T priority Critical patent/DE69827387T2/de
Publication of DE69827387D1 publication Critical patent/DE69827387D1/de
Application granted granted Critical
Publication of DE69827387T2 publication Critical patent/DE69827387T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Semiconductor Memories (AREA)
  • Liquid Crystal Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Corsets Or Brassieres (AREA)
DE69827387T 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms Expired - Lifetime DE69827387T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69827387T DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19701619 1997-01-17
DE19701619A DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms
PCT/US1998/000216 WO1998031362A1 (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
DE69827387T DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms

Publications (2)

Publication Number Publication Date
DE69827387D1 true DE69827387D1 (de) 2004-12-09
DE69827387T2 DE69827387T2 (de) 2005-10-27

Family

ID=7817708

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19701619A Expired - Lifetime DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE69827387T Expired - Lifetime DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19701619A Expired - Lifetime DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms

Country Status (24)

Country Link
EP (1) EP0989850B1 (de)
JP (2) JP4406685B2 (de)
KR (2) KR100761774B1 (de)
CN (1) CN1117564C (de)
AT (1) ATE281165T1 (de)
AU (1) AU723119B2 (de)
BG (1) BG64614B1 (de)
CA (1) CA2275379C (de)
CZ (1) CZ289863B6 (de)
DE (2) DE19701619B4 (de)
ES (1) ES2231959T3 (de)
FI (1) FI120135B (de)
HK (1) HK1024408A1 (de)
HU (1) HU226564B1 (de)
NO (1) NO321151B1 (de)
NZ (2) NZ510007A (de)
PL (1) PL190898B1 (de)
PT (1) PT989850E (de)
RO (1) RO120757B1 (de)
RU (1) RU2192252C2 (de)
SI (1) SI20060A (de)
SK (1) SK284264B6 (de)
WO (1) WO1998031362A1 (de)
ZA (1) ZA98420B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
CA2626249A1 (en) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
WO2007117431A2 (en) * 2006-04-03 2007-10-18 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of restless legs syndrome
TR200906997A1 (tr) 2009-09-11 2011-03-21 Sanovel �La� San. Ve T�C. A. �. Pramipeksol farmasötik bileşimleri.
TR200907554A1 (tr) 2009-10-06 2011-04-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Oral yolla dağılan pramıpexole bileşimleri.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3933738A1 (de) * 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4125446A1 (de) * 1991-08-01 1993-02-04 Uwe Dipl Ing Behmann Verfahren und einrichtung zur elektrischen kurzschlusspruefung und -ortung fuer leitungen, insbesondere fuer fahrleitungen elektrischer bahnen
US5598352A (en) * 1994-09-30 1997-01-28 Cirrus Logic, Inc. Method and apparatus for audio and video synchronizing in MPEG playback systems
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms

Also Published As

Publication number Publication date
BG64614B1 (bg) 2005-09-30
ATE281165T1 (de) 2004-11-15
NO321151B1 (no) 2006-03-27
PL334498A1 (en) 2000-02-28
KR20050085947A (ko) 2005-08-29
WO1998031362A1 (en) 1998-07-23
KR100761774B1 (ko) 2007-10-04
CN1243439A (zh) 2000-02-02
SK92099A3 (en) 2000-08-14
ES2231959T3 (es) 2005-05-16
CZ247899A3 (cs) 2000-01-12
CA2275379A1 (en) 1998-07-23
HK1024408A1 (en) 2000-10-13
PL190898B1 (pl) 2006-02-28
JP2001511158A (ja) 2001-08-07
KR20000070234A (ko) 2000-11-25
CN1117564C (zh) 2003-08-13
CA2275379C (en) 2006-11-28
JP2009062388A (ja) 2009-03-26
SK284264B6 (sk) 2004-12-01
RU2192252C2 (ru) 2002-11-10
JP4406685B2 (ja) 2010-02-03
HUP0001913A3 (en) 2002-09-30
BG103543A (en) 2000-04-28
CZ289863B6 (cs) 2002-04-17
NO993360D0 (no) 1999-07-07
NZ336804A (en) 2001-03-30
DE19701619B4 (de) 2007-10-11
ZA98420B (en) 1999-07-19
NO993360L (no) 1999-07-07
FI991616A (fi) 1999-07-16
EP0989850A1 (de) 2000-04-05
DE19701619A1 (de) 1998-07-23
FI120135B (fi) 2009-07-15
DE69827387T2 (de) 2005-10-27
PT989850E (pt) 2004-12-31
HU226564B1 (en) 2009-04-28
RO120757B1 (ro) 2006-07-28
SI20060A (sl) 2000-04-30
HUP0001913A2 (hu) 2000-11-28
AU6016898A (en) 1998-08-07
NZ510007A (en) 2004-11-26
EP0989850B1 (de) 2004-11-03
AU723119B2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69831406D1 (de) Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
DE60101669D1 (de) Verwendung von botulinum-toxin zur behandlung von diabetes
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE59109225D1 (de) Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
DE60017733D1 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE69701458D1 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
ATE273711T1 (de) Verwendung von niedermolekularem heparin zur behandlung und/oder prophylaxe motoneuronaler krankheiten
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE50003481D1 (de) Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, 552, DE

Owner name: PHARMACIA & UPJOHN COMPANY LLC, KALAMAZOO, MIC, US

8327 Change in the person/name/address of the patent owner

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, 552, DE